Knight Therapeutics Inc T.GUD

Alternate Symbol(s): KHTRF

Healthcare Biotechnology

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.

TSX:GUD - Post by User

Knight Therapeutics Inc

Bullboard Posts

Post by GoldenInvestoron Mar 04, 2020 12:18pm

145 Views

Post# 30765801

Effect of Addition of additional $49 million EBITDA on share

divided by 2, since only 51% is GUD's currently of BIOTOSCANA.

Thenwhat is the effect on share price.

I see precvious estimates of 3 million quarterly EBITDA

49/2 /4 =6 MILLION. With half of GBT

That that would be a 1/4 ly addition of 200% more EBITDA.

HOW WOULD THAT AFFECT A SHAREPICE?

please discuss

Bullboard Posts

Cizzle Brands, Changing Consumer Habits in Consumables